Insider Trading & Ownership of Fairmount Funds Management LLC

Location
West Conshohocken, PA
Summary
The estimated value of insider holdings of Fairmount Funds Management LLC is at least $1,162,916,984 dollars as of 22 Jan 2026. Fairmount Funds Management LLC is the Director of Cogent Biosciences, Inc. and owns shares of Cogent Biosciences, Inc. (COGT) stock worth about $798.96M. Fairmount Funds Management LLC is the Director, 10%+ Owner of Viridian Therapeutics, Inc.\DE and owns shares of Viridian Therapeutics, Inc.\DE (VRDN) stock worth about $86.12M. Fairmount Funds Management LLC is the Director, 10%+ Owner of CRESCENT BIOPHARMA, INC. and owns shares of CRESCENT BIOPHARMA, INC. (CBIO) stock worth about $60.56M. Fairmount Funds Management LLC is the Director, 10%+ Owner of Oruka Therapeutics, Inc. and owns shares of Oruka Therapeutics, Inc. (ORKA) stock worth about $54.32M. Fairmount Funds Management LLC is the Director, 10%+ Owner of Jade Biosciences, Inc. and owns shares of Jade Biosciences, Inc. (JBIO) stock worth about $48.08M. Fairmount Funds Management LLC is the Director of Dianthus Therapeutics, Inc. /DE/ and owns shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) stock worth about $42.4M. Fairmount Funds Management LLC is the Director of Zenas BioPharma, Inc. and owns shares of Zenas BioPharma, Inc. (ZBIO) stock worth about $41.97M. Fairmount Funds Management LLC is the Director of Apogee Therapeutics, Inc. and owns shares of Apogee Therapeutics, Inc. (APGE) stock worth about $30.51M.
Signature
/s/ Tomas Kiselak for Fairmount Funds Management LLC
All Insider Reports
All Insider Reports

Notify me when Fairmount Funds Management LLC files a new Insider Trading report.

⭐ Subscribe ⭐

Ownership of Fairmount Funds Management LLC

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
COGT Cogent Biosciences, Inc. Director $798,960,735 -$102,400,007 -11% 22 Jan 2026
VRDN Viridian Therapeutics, Inc.\DE Director, 10%+ Owner $86,118,076 +$9,999,990 +13% 23 Oct 2025
CBIO CRESCENT BIOPHARMA, INC. Director, 10%+ Owner $60,557,872 +$19,999,999 +49% 04 Dec 2025
ORKA Oruka Therapeutics, Inc. Director, 10%+ Owner $54,318,009 17 Sep 2025
JBIO Jade Biosciences, Inc. Director, 10%+ Owner $48,084,557 06 Oct 2025
DNTH Dianthus Therapeutics, Inc. /DE/ Director $42,395,456 27 Sep 2024
ZBIO Zenas BioPharma, Inc. Director $41,971,475 +$6,008,161 +17% 07 Oct 2025
APGE Apogee Therapeutics, Inc. Director $30,510,804 -$133,525,000 -81% 22 Jan 2026
GLTO Galecto, Inc. Director, 10%+ Owner 10 Nov 2025
SYRE Spyre Therapeutics, Inc. Director 29 May 2025

Insider Transactions Reported by Fairmount Funds Management LLC:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.